SETTING: Bujumbura, Burundi. OBJECTIVES: To determine resistance levels of Mycobacterium tuberculosis (TB) to the main anti-tuberculosis drugs after 11 years of a DOTS programme using a WHO-recommended partially intermittent 6-month rifampicin (RMP) first-line regimen and fixed-dose drug combinations (FDCs). DESIGN: Drug susceptibility testing of systematic samples of M. tuberculosis isolated from newly registered sputum smear-positive cases in the capital during a 15-month period (2002-2003). RESULTS: Of 496 strains from new cases, 16.1% showed resistance to any drug, 6.3% to isoniazid (INH), 2.0% to RMP (1.4% multidrug-resistant TB [MDR-TB]), 13.3% to streptomycin and 1.6% to ethambutol. Among 69 strains from previously treated cases, the prevalence of resistance was 30%, 19%, 15% (12% MDR-TB strains), 25% and 6%, respectively. CONCLUSION: Levels of drug resistance in Bujumbura are higher than average for Africa, despite long-term use of the DOTS strategy with FDCs and a ban on sales of TB drugs. Most worrying is the appearance of MDR-TB and RMP-resistant, INH-susceptible strains in new cases. Although a survey cannot prove that high HIV prevalence, elevated levels of resistance to some other drugs and irregular intake allowed acquisition of drug resistance, the effectiveness and safety of 6-month regimens with (partially) intermittent RMP throughout under such conditions should be investigated.
SETTING: Bujumbura, Burundi. OBJECTIVES: To determine resistance levels of Mycobacterium tuberculosis (TB) to the main anti-tuberculosis drugs after 11 years of a DOTS programme using a WHO-recommended partially intermittent 6-month rifampicin (RMP) first-line regimen and fixed-dose drug combinations (FDCs). DESIGN: Drug susceptibility testing of systematic samples of M. tuberculosis isolated from newly registered sputum smear-positive cases in the capital during a 15-month period (2002-2003). RESULTS: Of 496 strains from new cases, 16.1% showed resistance to any drug, 6.3% to isoniazid (INH), 2.0% to RMP (1.4% multidrug-resistant TB [MDR-TB]), 13.3% to streptomycin and 1.6% to ethambutol. Among 69 strains from previously treated cases, the prevalence of resistance was 30%, 19%, 15% (12% MDR-TB strains), 25% and 6%, respectively. CONCLUSION: Levels of drug resistance in Bujumbura are higher than average for Africa, despite long-term use of the DOTS strategy with FDCs and a ban on sales of TB drugs. Most worrying is the appearance of MDR-TB and RMP-resistant, INH-susceptible strains in new cases. Although a survey cannot prove that high HIV prevalence, elevated levels of resistance to some other drugs and irregular intake allowed acquisition of drug resistance, the effectiveness and safety of 6-month regimens with (partially) intermittent RMP throughout under such conditions should be investigated.
Authors: Courtney M Yuen; Helen E Jenkins; Carly A Rodriguez; Salmaan Keshavjee; Mercedes C Becerra Journal: Pediatrics Date: 2015-06-01 Impact factor: 7.124
Authors: M J Nasiri; S Zamani; A Pormohammad; M M Feizabadi; H R Aslani; M Amin; R Halabian; A A Imani Fooladi Journal: Eur J Clin Microbiol Infect Dis Date: 2017-08-19 Impact factor: 3.267
Authors: Helen E Jenkins; Arielle W Tolman; Courtney M Yuen; Jonathan B Parr; Salmaan Keshavjee; Carlos M Pérez-Vélez; Marcello Pagano; Mercedes C Becerra; Ted Cohen Journal: Lancet Date: 2014-03-24 Impact factor: 79.321
Authors: L T Daum; O S Konstantynovska; O S Solodiankin; O O Liashenko; P I Poteiko; V I Bolotin; I I Hrek; A V Rohozhyn; J D Rodriguez; G W Fischer; J P Chambers; A P Gerilovych Journal: J Clin Microbiol Date: 2018-05-25 Impact factor: 5.948
Authors: F K Mukinda; D Theron; G D van der Spuy; K R Jacobson; M Roscher; E M Streicher; A Musekiwa; G J Coetzee; T C Victor; B J Marais; J B Nachega; R M Warren; H S Schaaf Journal: Int J Tuberc Lung Dis Date: 2012-02 Impact factor: 2.373
Authors: A Dramowski; M M Morsheimer; A M Jordaan; T C Victor; P R Donald; H S Schaaf Journal: Int J Tuberc Lung Dis Date: 2012-01 Impact factor: 2.373
Authors: Benson R Kidenya; Lauren E Webster; Sehan Behan; Rodrick Kabangila; Robert N Peck; Stephen E Mshana; Oksana Ocheretina; Daniel W Fitzgerald Journal: Tuberculosis (Edinb) Date: 2013-09-07 Impact factor: 3.131
Authors: Courtney M Yuen; Arielle W Tolman; Ted Cohen; Jonathan B Parr; Salmaan Keshavjee; Mercedes C Becerra Journal: Pediatr Infect Dis J Date: 2013-05 Impact factor: 2.129